Literature DB >> 27034394

Transgenic Mouse Models of SV40-Induced Cancer.

Amanda L Hudson1, Emily K Colvin1.   

Abstract

The SV40 viral oncogene has been used since the 1970s as a reliable and reproducible method to generate transgenic mouse models. This seminal discovery has taught us an immense amount about how tumorigenesis occurs, and its success has led to the evolution of many mouse models of cancer. Despite the development of more modern and targeted approaches for developing genetically engineered mouse models of cancer, SV40-induced mouse models still remain frequently used today. This review discusses a number of cancer types in which SV40 mouse models of cancer have been developed and highlights their relevance and importance to preclinical research.
© The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  SV40; cancer; mouse model; transgenic

Mesh:

Year:  2016        PMID: 27034394     DOI: 10.1093/ilar/ilw001

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  3 in total

Review 1.  Functional Domains of the Early Proteins and Experimental and Epidemiological Studies Suggest a Role for the Novel Human Polyomaviruses in Cancer.

Authors:  Ugo Moens; Carla Prezioso; Valeria Pietropaolo
Journal:  Front Microbiol       Date:  2022-02-18       Impact factor: 5.640

2.  Murine Models of Chronic Viral Infections and Associated Cancers.

Authors:  D V Avdoshina; A S Kondrashova; M G Belikova; E O Bayurova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

3.  Generation and Characterization of Immortalized Mouse Cortical Astrocytes From Wildtype and Connexin43 Knockout Mice.

Authors:  Antonio Cibelli; Sandra Veronica Lopez-Quintero; Sean Mccutcheon; Eliana Scemes; David C Spray; Randy F Stout; Sylvia O Suadicani; Mia M Thi; Marcia Urban-Maldonado
Journal:  Front Cell Neurosci       Date:  2021-03-15       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.